Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2017

View Archived Issues

Preclinical characterization of a novel selective PI3Kalpha inhibitor, GDC-0077

LY-3214996 demonstrates potent antitumor activity in cancer models with MAPK pathway alterations

Discovery and preclinical characterization of novel JAK1 inhibitor AZD-4205

FDA approves Gilead Sciences' Harvoni and Sovaldi in pediatric patients

First data from first-in-human study of FGFR-4 inhibitor FGF-401 reported

Janssen identifies novel FGFR inhibitors

NSTDA patents dihydrofolate reductase inhibitors

Merck KGaA discloses new IRAK-1/4 inhibitors

IASOtoc now available in France, Austria and Germany

Phase II PREVACEbola vaccine study launched in West Africa to evaluate three vaccination strategies

Akorn and Fresenius Kabi in discussions regarding potential acquisition

PeptiDream and Janssen enter discovery and collaboration agreement

Kyowa Hakko Kirin announces positive results from the phase III MAVORIC clinical trial

Themis Bioscience initiates phase I dose-finding study of MV-ZIKA vaccine

Kura Oncology begins phase I study of KO-947 in nonhematological malignancies

Sunshine Lake Pharma, Calitor Sciences patent JAK, FLT-3 and Aurora kinase inhibitors

Medivir announces completion of phase II remetinostat study in CTCL

Assembly Biosciences, IURTC present HBV core protein modulators

Fred Hutch announces faculty and staff achievements

FDA issues complete response letter regarding Merck & Co.'s sitagliption sNDAs

Celgene describes in vivo antitumor activity of anti-CD47 monoclonal antibody CC-90002

Cipla and MEDRx enter into a collaboration for MRX-4TZT

Nanotherapeutics begins enrollment in phase I trial of NTM-1634

Indian FDA approves first autologous dendritic cell-based immuno-oncology product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...